Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 26.05
SRPT's Cash to Debt is ranked lower than
54% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. SRPT: 26.05 )
Ranked among companies with meaningful Cash to Debt only.
SRPT' s 10-Year Cash to Debt Range
Min: 4.43  Med: 10000.00 Max: No Debt
Current: 26.05
F-Score: 2
Z-Score: 14.10
M-Score: -4.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1747.77
SRPT's Operating margin (%) is ranked lower than
83% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. SRPT: -1747.77 )
Ranked among companies with meaningful Operating margin (%) only.
SRPT' s 10-Year Operating margin (%) Range
Min: -28680.87  Med: -1371.21 Max: -71.16
Current: -1747.77
-28680.87
-71.16
Net-margin (%) -1732.86
SRPT's Net-margin (%) is ranked lower than
83% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. SRPT: -1732.86 )
Ranked among companies with meaningful Net-margin (%) only.
SRPT' s 10-Year Net-margin (%) Range
Min: -27020  Med: -1391.71 Max: -4.93
Current: -1732.86
-27020
-4.93
ROE (%) -66.91
SRPT's ROE (%) is ranked lower than
71% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. SRPT: -66.91 )
Ranked among companies with meaningful ROE (%) only.
SRPT' s 10-Year ROE (%) Range
Min: -309.2  Med: -75.29 Max: -16.44
Current: -66.91
-309.2
-16.44
ROA (%) -57.53
SRPT's ROA (%) is ranked lower than
73% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. SRPT: -57.53 )
Ranked among companies with meaningful ROA (%) only.
SRPT' s 10-Year ROA (%) Range
Min: -184.14  Med: -62.30 Max: -4.62
Current: -57.53
-184.14
-4.62
ROC (Joel Greenblatt) (%) -500.12
SRPT's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. SRPT: -500.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SRPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2075  Med: -556.33 Max: -277.71
Current: -500.12
-2075
-277.71
Revenue Growth (3Y)(%) -52.10
SRPT's Revenue Growth (3Y)(%) is ranked lower than
83% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SRPT: -52.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SRPT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -63.2  Med: 10.50 Max: 383.5
Current: -52.1
-63.2
383.5
EBITDA Growth (3Y)(%) 26.60
SRPT's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. SRPT: 26.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SRPT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -36.3  Med: 1.65 Max: 43.4
Current: 26.6
-36.3
43.4
EPS Growth (3Y)(%) 213.50
SRPT's EPS Growth (3Y)(%) is ranked higher than
100% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. SRPT: 213.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SRPT' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.4  Med: -1.40 Max: 213.5
Current: 213.5
-62.4
213.5
» SRPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SRPT Guru Trades in Q3 2014

Columbia Wanger 3,237,000 sh (+22.94%)
Steven Cohen 691,200 sh (unchged)
Steven Cohen 227,300 sh (-16.46%)
George Soros 325,000 sh (-52.21%)
» More
Q4 2014

SRPT Guru Trades in Q4 2014

Jim Simons 164,278 sh (New)
Steven Cohen 1,551,300 sh (+582.49%)
Steven Cohen 1,826,500 sh (+17.74%)
Columbia Wanger 3,272,400 sh (+1.09%)
Columbia Wanger 3,272,400 sh (unchged)
Steven Cohen 275,200 sh (unchged)
George Soros Sold Out
» More
Q1 2015

SRPT Guru Trades in Q1 2015

Jim Simons 396,539 sh (+141.38%)
Steven Cohen 1,702,200 sh (+9.73%)
Steven Cohen 174,900 sh (unchged)
Columbia Wanger 3,272,400 sh (unchged)
» More
2015

SRPT Guru Trades in 2015

Steven Cohen 2,193,600 sh (+28.87%)
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.86
SRPT's P/B is ranked lower than
63% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. SRPT: 6.86 )
Ranked among companies with meaningful P/B only.
SRPT' s 10-Year P/B Range
Min: 2  Med: 4.61 Max: 234
Current: 6.86
2
234
P/S 373.46
SRPT's P/S is ranked lower than
93% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. SRPT: 373.46 )
Ranked among companies with meaningful P/S only.
SRPT' s 10-Year P/S Range
Min: 1.56  Med: 24.88 Max: 2244
Current: 373.46
1.56
2244
EV-to-EBIT -7.18
SRPT's EV-to-EBIT is ranked lower than
473% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. SRPT: -7.18 )
Ranked among companies with meaningful EV-to-EBIT only.
SRPT' s 10-Year EV-to-EBIT Range
Min: -29.1  Med: -5.20 Max: -0.8
Current: -7.18
-29.1
-0.8
Current Ratio 5.69
SRPT's Current Ratio is ranked higher than
58% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. SRPT: 5.69 )
Ranked among companies with meaningful Current Ratio only.
SRPT' s 10-Year Current Ratio Range
Min: 0.76  Med: 7.65 Max: 36.25
Current: 5.69
0.76
36.25
Quick Ratio 5.69
SRPT's Quick Ratio is ranked higher than
59% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. SRPT: 5.69 )
Ranked among companies with meaningful Quick Ratio only.
SRPT' s 10-Year Quick Ratio Range
Min: 0.76  Med: 7.65 Max: 36.25
Current: 5.69
0.76
36.25
Days Sales Outstanding 90.38
SRPT's Days Sales Outstanding is ranked lower than
69% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. SRPT: 90.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRPT' s 10-Year Days Sales Outstanding Range
Min: 28.22  Med: 90.50 Max: 886.65
Current: 90.38
28.22
886.65

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.13
SRPT's Price/Net Cash is ranked lower than
58% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. SRPT: 11.13 )
Ranked among companies with meaningful Price/Net Cash only.
SRPT' s 10-Year Price/Net Cash Range
Min: 3.03  Med: 6.36 Max: 72.6
Current: 11.13
3.03
72.6
Price/Net Current Asset Value 9.18
SRPT's Price/Net Current Asset Value is ranked lower than
56% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. SRPT: 9.18 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SRPT' s 10-Year Price/Net Current Asset Value Range
Min: 2.95  Med: 6.08 Max: 42
Current: 9.18
2.95
42
Price/Tangible Book 7.11
SRPT's Price/Tangible Book is ranked lower than
56% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. SRPT: 7.11 )
Ranked among companies with meaningful Price/Tangible Book only.
SRPT' s 10-Year Price/Tangible Book Range
Min: 2.41  Med: 4.85 Max: 474
Current: 7.11
2.41
474
Price/Median PS Value 14.96
SRPT's Price/Median PS Value is ranked lower than
98% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. SRPT: 14.96 )
Ranked among companies with meaningful Price/Median PS Value only.
SRPT' s 10-Year Price/Median PS Value Range
Min: 0.08  Med: 2.92 Max: 76.32
Current: 14.96
0.08
76.32
Earnings Yield (Greenblatt) (%) -13.96
SRPT's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SRPT: -13.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SRPT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -53.7  Med: 0.00 Max: 82
Current: -13.96
-53.7
82

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:AB3A.Germany,
Sarepta Therapeutics Inc was incorporated in the State of Oregon on July 22, 1980. The Company discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The Company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases.
» More Articles for NAS:SRPT

Headlines

Articles On GuruFocus.com
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Feb 16 2013 

More From Other Websites
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 31 2015
Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data... Jul 30 2015
Sarepta Therapeutics to Announce Second Quarter 2015 Financial Results and Recent Corporate... Jul 30 2015
Sarepta Therapeutics to Announce Second Quarter 2015 Financial Results and Recent Corporate... Jul 30 2015
Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data... Jul 22 2015
​Short sellers retreat from Sarepta and OvaScience Jul 20 2015
FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs Jul 20 2015
​Sarepta makes plans to start late-stage tests of two more Duchenne drugs Jul 17 2015
Sarepta Soars on FDA Submission for Duchenne Drug Jul 16 2015
Sarepta Therapeutics One Step Closer to Drug Approval Jul 03 2015
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jul 02 2015
The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta -... Jul 02 2015
Cramer Worried About Airline Overcapacity, Hints at Surprise McDonald's Piece Jul 01 2015
Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress -... Jul 01 2015
Sarepta Hires ex-Genzyme Head Henri Termeer as Adviser Jul 01 2015
Sarepta Therapeutics Appoints Henri Termeer as Advisor to the Company Jul 01 2015
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 30 2015
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments... Jun 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK